Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reb-TASK3-siRNA is a chemically conjugated small interfering RNA (siRNA) specifically designed to knock down the expression of the TASK3 potassium channel in norepinephrine (NE) neurons. The siRNA is conjugated to reboxetine, a norepinephrine transporter ligand, to enable targeted delivery and selective accumulation within NE neurons, particularly after intranasal administration. By silencing TASK3 (K2P9.1 or KCNK9), the drug is intended to produce antidepressant-like effects through neuronal-specific gene knockdown. Preclinical research demonstrates that Reb-TASK3-siRNA reduces TASK3 mRNA and protein in monoaminergic brainstem cell groups, resulting in enhanced antidepressant-like behaviors in mouse models. This supports the therapeutic potential of RNAi-based targeting of TASK3 for major depressive disorder and possibly related neuropsychiatric indications[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reb-TASK3-siRNA.